128 related articles for article (PubMed ID: 38607246)
21. Molecular diagnostics in the management of rhabdomyosarcoma.
Arnold MA; Barr FG
Expert Rev Mol Diagn; 2017 Feb; 17(2):189-194. PubMed ID: 28058850
[TBL] [Abstract][Full Text] [Related]
22. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation.
Mehra S; de la Roza G; Tull J; Shrimpton A; Valente A; Zhang S
Diagn Mol Pathol; 2008 Mar; 17(1):14-20. PubMed ID: 18303411
[TBL] [Abstract][Full Text] [Related]
23. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
[TBL] [Abstract][Full Text] [Related]
24. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma.
Mosquera JM; Sboner A; Zhang L; Kitabayashi N; Chen CL; Sung YS; Wexler LH; LaQuaglia MP; Edelman M; Sreekantaiah C; Rubin MA; Antonescu CR
Genes Chromosomes Cancer; 2013 Jun; 52(6):538-50. PubMed ID: 23463663
[TBL] [Abstract][Full Text] [Related]
25. FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes.
Goldstein M; Meller I; Orr-Urtreger A
Genes Chromosomes Cancer; 2007 Nov; 46(11):1028-38. PubMed ID: 17696196
[TBL] [Abstract][Full Text] [Related]
26. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
27. Establishment and Characterization of a Cell Line (S-RMS1) Derived from an Infantile Spindle Cell Rhabdomyosarcoma with
Colletti M; Galardi A; Miele E; Di Paolo V; Russo I; De Stefanis C; De Vito R; Rinelli M; Ciolfi A; De Angelis B; Zin A; Guffanti A; Digilio MC; Novelli A; Alaggio R; Milano GM; Di Giannatale A
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34067464
[No Abstract] [Full Text] [Related]
28. MYOD1 as a prognostic indicator in rhabdomyosarcoma.
Ahmed AA; Habeebu S; Farooqi MS; Gamis AS; Gonzalez E; Flatt T; Sherman A; Surrey L; Arnold MA; Conces M; Koo S; Dioufa N; Barr FG; Tsokos MG
Pediatr Blood Cancer; 2021 Sep; 68(9):e29085. PubMed ID: 33913590
[TBL] [Abstract][Full Text] [Related]
29. Genomic profiling of pleomorphic rhabdomyosarcoma reveals a genomic signature distinct from that of embryonal rhabdomyosarcoma.
Saoud C; Dermawan JK; Sharma AE; Tap W; Wexler LH; Antonescu CR
Genes Chromosomes Cancer; 2024 May; 63(5):e23238. PubMed ID: 38722224
[TBL] [Abstract][Full Text] [Related]
30. Molecular biology of rhabdomyosarcoma.
Gallego Melcón S; Sánchez de Toledo Codina J
Clin Transl Oncol; 2007 Jul; 9(7):415-9. PubMed ID: 17652054
[TBL] [Abstract][Full Text] [Related]
31. Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
Nishimura R; Takita J; Sato-Otsubo A; Kato M; Koh K; Hanada R; Tanaka Y; Kato K; Maeda D; Fukayama M; Sanada M; Hayashi Y; Ogawa S
Cancer Sci; 2013 Jul; 104(7):856-64. PubMed ID: 23578105
[TBL] [Abstract][Full Text] [Related]
32. Histopathological, immunohistochemical and molecular cytogenetic analysis of 21 spindle cell/sclerosing rhabdomyosarcomas.
Rekhi B; Singhvi T
APMIS; 2014 Nov; 122(11):1144-52. PubMed ID: 24730567
[TBL] [Abstract][Full Text] [Related]
33. SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma.
Karanian M; Pissaloux D; Gomez-Brouchet A; Chevenet C; Le Loarer F; Fernandez C; Minard V; Corradini N; Castex MP; Duc-Gallet A; Blay JY; Tirode F
Am J Surg Pathol; 2020 May; 44(5):607-616. PubMed ID: 32187044
[TBL] [Abstract][Full Text] [Related]
34. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
[TBL] [Abstract][Full Text] [Related]
35. Spindle Cell/Sclerosing Rhabdomyosarcoma With
Rakheja D; Park JY; Alhasan M; Uddin N
Int J Surg Pathol; 2022 Dec; 30(8):950-955. PubMed ID: 35466752
[TBL] [Abstract][Full Text] [Related]
36. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
[TBL] [Abstract][Full Text] [Related]
37. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
38. FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma.
Liu J; Guzman MA; Pezanowski D; Patel D; Hauptman J; Keisling M; Hou SJ; Papenhausen PR; Pascasio JM; Punnett HH; Halligan GE; de Chadarévian JP
Mod Pathol; 2011 Oct; 24(10):1327-35. PubMed ID: 21666686
[TBL] [Abstract][Full Text] [Related]
39. Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype.
Kohashi K; Oda Y; Yamamoto H; Tamiya S; Takahira T; Takahashi Y; Tajiri T; Taguchi T; Suita S; Tsuneyoshi M
J Cancer Res Clin Oncol; 2008 Oct; 134(10):1097-103. PubMed ID: 18386058
[TBL] [Abstract][Full Text] [Related]
40. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
